Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent GBM

• W. Geens,
• S. Du Four,
• S. Van Laere,
• J.K. Schwarze,
• G. Awada,
• J. Tijtgat,
• M. Bruneau,
• H. Everaert,
• B. Neyns,
• J. Duerinck

Affiliations

W. Geens

UZ Brussels, Department of Neurosurgery, Brussels, Belgium

S. Du Four

UZ Brussels, Department of Neurosurgery, Brussels, Belgium

S. Van Laere

Free University of Brussels, Interfaculty Center Data Processing and Statistics, Brussels, Belgium

J.K. Schwarze

UZ Brussels, Department of Medical Oncology, Brussels, Belgium

G. Awada

UZ Brussels, Department of Medical Oncology, Brussels, Belgium

J. Tijtgat

UZ Brussels, Department of Medical Oncology, Brussels, Belgium

M. Bruneau

UZ Brussels, Department of Neurosurgery, Brussels, Belgium

H. Everaert

UZ Brussels, Department of Nuclear Medicine, Brussels, Belgium

B. Neyns

UZ Brussels, Department of Medical Oncology, Brussels, Belgium

J. Duerinck

UZ Brussels, Department of Neurosurgery, Brussels, Belgium